Dr. Borgia also holds the positions of Director of the Rush Biomarker Development Core as well as the Rush Translational Cancer Research Graduate Program. His research is focused on developing novel “-omics” diagnostic tests for profiling patient specimens and providing mechanistic insights for pathophysiology. Dr. Borgia oversees the collection and annotation of patient specimens for translational research projects and ongoing clinical trials at the Rush University Cancer Center. Additionally, at the Core, he and his team work on discovery and development of new/novel biomarkers for use in diagnostics.